{"id":78771,"date":"2026-03-23T12:06:18","date_gmt":"2026-03-23T12:06:18","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/"},"modified":"2026-03-23T12:06:18","modified_gmt":"2026-03-23T12:06:18","slug":"nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/","title":{"rendered":"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit"},"content":{"rendered":"<div>\n<p>CRANBERRY TOWNSHIP, Pa., March  23, 2026  (GLOBE NEWSWIRE) &#8212; N\u00d6K Therapeutics, Inc. (\u201cN\u00d6K\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company advancing autologous Natural Killer (\u201cNK\u201d) cell immunotherapies, today announced that its Chief Executive Officer and Co-Founder, Robert Lewis, will participate as a featured speaker at the 11th Annual Innate Killer Summit, taking place March 24\u201325, 2026, in San Diego, California.<\/p>\n<p>The Innate Killer Summit is a leading global forum focused on advancing NK-cell therapies across oncology and autoimmune diseases, convening biotechnology leaders, investors, and academic experts to discuss clinical progress, innovation, and commercialization strategies.<\/p>\n<p>Mr. Lewis will participate in the CEO Think Tank panel on March 24, addressing key inflection points in innate immunotherapy, including clinical development challenges, investment dynamics, and the future direction of NK-cell platforms.<\/p>\n<p>In addition, Mr. Lewis will deliver a featured presentation titled:<br \/>\u201cDurable Long-Term Survival Following Autologous NK-Cell Consolidation in Multiple Myeloma: Phase I Data with Extended Follow-Up.\u201d<\/p>\n<p>The presentation will highlight:<\/p>\n<ul>\n<li>Sustained long-term survival outcomes in ASCT-eligible multiple myeloma patients<\/li>\n<li>Durable responses in high-risk patient populations<\/li>\n<li>Advancement toward Phase II development, including multi-center expansion and combination strategies<\/li>\n<\/ul>\n<p>These findings represent one of the longest follow-up datasets reported for autologous NK-cell therapy and support NK-cell consolidation as a differentiated approach in multiple myeloma.<\/p>\n<p><u>N\u00d6K\u2019s platform is designed to address key challenges in cell therapy by enabling treatment without lymphodepleting chemotherapy<\/u>, preserving host immune function, and supporting outpatient administration, with the goal of expanding patient access while maintaining durable clinical responses.<\/p>\n<p>\u201cWe are pleased to present our long-term clinical data at the Innate Killer Summit,\u201d said Robert Lewis, CEO of N\u00d6K Therapeutics. \u201cOur results continue to support the potential for autologous NK-cell therapy to deliver durable outcomes with a favorable safety profile as we advance toward Phase II.\u201d<\/p>\n<p><strong>About N\u00d6K Therapeutics, Inc.<\/strong><br \/>N\u00d6K Therapeutics is a clinical-stage biotechnology company developing autologous NK-cell immunotherapies for oncology. Its platform is designed for administration without lymphodepleting chemotherapy, preservation of immune function, and outpatient delivery.<\/p>\n<p><strong>N\u00d6K Media\/Investor Contact:<\/strong><br \/>Shane Hackett<br \/>MarketLeverage, LLC<br \/>shane@marketleverage.com<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDk3YTVmOTQtMTM2YS00N2Q5LWFkZjAtOTQzYzA5NmZlNGE2LTEzMTgyNTAtMjAyNi0wMy0yMy1lbg==\/tiny\/N-K-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CRANBERRY TOWNSHIP, Pa., March 23, 2026 (GLOBE NEWSWIRE) &#8212; N\u00d6K Therapeutics, Inc. (\u201cN\u00d6K\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company advancing autologous Natural Killer (\u201cNK\u201d) cell immunotherapies, today announced that its Chief Executive Officer and Co-Founder, Robert Lewis, will participate as a featured speaker at the 11th Annual Innate Killer Summit, taking place March 24\u201325, [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-78771","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit\" \/>\n<meta property=\"og:description\" content=\"CRANBERRY TOWNSHIP, Pa., March 23, 2026 (GLOBE NEWSWIRE) &#8212; N\u00d6K Therapeutics, Inc. (\u201cN\u00d6K\u201d or the \u201cCompany\u201d), a clinical-stage biotechno\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T12:06:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/NDk3YTVmOTQtMTM2YS00N2Q5LWFkZjAtOTQzYzA5NmZlNGE2LTEzMTgyNTAtMjAyNi0wMy0yMy1lbg==\/tiny\/N-K-Therapeutics-Inc-.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit\",\"datePublished\":\"2026-03-23T12:06:18+00:00\",\"dateModified\":\"2026-03-23T12:06:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/\"},\"wordCount\":352,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/\",\"name\":\"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-03-23T12:06:18+00:00\",\"dateModified\":\"2026-03-23T12:06:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/","og_locale":"en_US","og_type":"article","og_title":"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit","og_description":"CRANBERRY TOWNSHIP, Pa., March 23, 2026 (GLOBE NEWSWIRE) &#8212; N\u00d6K Therapeutics, Inc. (\u201cN\u00d6K\u201d or the \u201cCompany\u201d), a clinical-stage biotechno","og_url":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-03-23T12:06:18+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/NDk3YTVmOTQtMTM2YS00N2Q5LWFkZjAtOTQzYzA5NmZlNGE2LTEzMTgyNTAtMjAyNi0wMy0yMy1lbg==\/tiny\/N-K-Therapeutics-Inc-.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit","datePublished":"2026-03-23T12:06:18+00:00","dateModified":"2026-03-23T12:06:18+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/"},"wordCount":352,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/","url":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/","name":"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-03-23T12:06:18+00:00","dateModified":"2026-03-23T12:06:18+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/nok-therapeutics-to-present-long-term-clinical-data-at-the-11th-annual-innate-killer-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"N\u00d6K Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=78771"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78771\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=78771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=78771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=78771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}